These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16706683)

  • 1. Targeting glycogen synthase kinase-3 in insulin signalling.
    Frame S; Zheleva D
    Expert Opin Ther Targets; 2006 Jun; 10(3):429-44. PubMed ID: 16706683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor.
    Ruzzin J; Wagman AS; Jensen J
    Diabetologia; 2005 Oct; 48(10):2119-30. PubMed ID: 16078016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.
    MacAulay K; Woodgett JR
    Expert Opin Ther Targets; 2008 Oct; 12(10):1265-74. PubMed ID: 18781825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.
    Eldar-Finkelman H; Ilouz R
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibitors of glycogen synthase kinase 3.
    Meijer L; Flajolet M; Greengard P
    Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
    Van Wauwe J; Haefner B
    Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.
    Woodgett JR
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):281-90. PubMed ID: 14683459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?
    Garcea G; Manson MM; Neal CP; Pattenden CJ; Sutton CD; Dennison AR; Berry DP
    Curr Cancer Drug Targets; 2007 May; 7(3):209-15. PubMed ID: 17504118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
    Gould TD
    Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase 3: a key regulator of cellular fate.
    Forde JE; Dale TC
    Cell Mol Life Sci; 2007 Aug; 64(15):1930-44. PubMed ID: 17530463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling.
    Sharfi H; Eldar-Finkelman H
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E307-15. PubMed ID: 18029441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GSK-3 family as therapeutic target for myocardial diseases.
    Lal H; Ahmad F; Woodgett J; Force T
    Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
    Huang HC; Klein PS
    Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes.
    Kaidanovich O; Eldar-Finkelman H
    Expert Opin Ther Targets; 2002 Oct; 6(5):555-61. PubMed ID: 12387679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
    Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
    Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
    Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
    Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.